These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 26485764

  • 1. The quest for GAS vaccine.
    Pandey M, Good MF.
    Oncotarget; 2015 Oct 27; 6(33):34063-4. PubMed ID: 26485764
    [No Abstract] [Full Text] [Related]

  • 2. The emm-type diversity does not always reflect the M protein genetic diversity--is there a case for designer vaccine against GAS.
    Smeesters PR, Dramaix M, Van Melderen L.
    Vaccine; 2010 Jan 22; 28(4):883-5. PubMed ID: 19963033
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.
    Pandey M, Mortensen R, Calcutt A, Powell J, Batzloff MR, Dietrich J, Good MF.
    J Immunol; 2016 Apr 15; 196(8):3364-74. PubMed ID: 26969753
    [Abstract] [Full Text] [Related]

  • 5. Immunity to group a streptococcal M proteins: forging a single-edged sword.
    Madoff LC.
    Clin Infect Dis; 2005 Oct 15; 41(8):1123-4. PubMed ID: 16163630
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Contribution of cryptic epitopes in designing a group A streptococcal vaccine.
    Ozberk V, Pandey M, Good MF.
    Hum Vaccin Immunother; 2018 Oct 15; 14(8):2034-2052. PubMed ID: 29873591
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.
    Tsoi SK, Smeesters PR, Frost HR, Licciardi P, Steer AC.
    J Immunol Res; 2015 Oct 15; 2015():167089. PubMed ID: 26101780
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Strategies in the development of vaccines to prevent infections with group A streptococcus.
    Good MF, Batzloff MR, Pandey M.
    Hum Vaccin Immunother; 2013 Nov 15; 9(11):2393-7. PubMed ID: 23863455
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.
    Batzloff MR, Fane A, Gorton D, Pandey M, Rivera-Hernandez T, Calcutt A, Yeung G, Hartas J, Johnson L, Rush CM, McCarthy J, Ketheesan N, Good MF.
    Hum Vaccin Immunother; 2016 Dec 15; 12(12):3089-3096. PubMed ID: 27541593
    [Abstract] [Full Text] [Related]

  • 18. Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.
    Wozniak A, Scioscia N, García PC, Dale JB, Paillavil BA, Legarraga P, Salazar-Echegarai FJ, Bueno SM, Kalergis AM.
    Microbiol Immunol; 2018 Jun 15; 62(6):395-404. PubMed ID: 29704396
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.